Calibrate was early to the GLP-1 medication wave before Ozempic became a household word, and that timing created enormous early tailwinds. They raised $100M in their Series B at exactly the moment investors were desperate to back the metabolic health category. The turbulence came fast — significant layoffs in 2022, a pivot away from insurance reimbursement, and a shift to a higher-cost cash-pay model. The product still works, the market is real, but execution has been bumpy. Calibrate is a cautionary tale about raising too much capital too fast in a category that was still figuring out its distribution model.
Founded
2019
HQ
New York, USA
Total Raised
$123 million
Founder
Isabelle Kenyon
Status
Private
Website
www.joincalibrate.comTHE ORIGIN STORY
Isabelle Kenyon spent years working in health policy and became frustrated that obesity was treated as a willpower problem rather than a metabolic disease. She founded Calibrate in 2019 with the thesis that GLP-1 medications combined with lifestyle coaching could produce durable weight loss outcomes that traditional diets never could.
The company launched its program in 2020, right as the pandemic drove a spike in telehealth adoption. The first version combined a physician consultation, a GLP-1 prescription, and a dedicated metabolic coach.
WHAT THEY ACTUALLY DO
Subscription-based metabolic health program. Members pay a monthly fee for access to physician oversight, GLP-1 medication prescriptions and management, and one-on-one coaching focused on food, sleep, exercise and emotional health.
The program is designed as a one-year commitment. Calibrate initially pursued health insurance reimbursement but pivoted to a cash-pay model as insurance coverage for GLP-1 medications proved inconsistent and slow to expand.
THE PRODUCTS
[ "Calibrate Metabolic Reset — the core one-year program combining GLP-1 medication management, physician oversight and lifestyle coaching", "Calibrate for Employers — a version sold through corporate benefits programs to cover employee metabolic health costs" ]
HOW THEY GREW
Ride the GLP-1 tailwind (Ozempic, Wegovy, Mounjaro) by making medication access simpler and wrapping it with clinical oversight and coaching that pure medication platforms do not provide. The coaching differentiation is the moat argument — anyone can prescribe Ozempic via telehealth, but Calibrate pairs it with behavioral support that is supposed to make outcomes more durable.
Employer partnerships are a secondary growth channel.
THE HARD PART
The cost. GLP-1 medications are expensive — often $1,000+ per month without insurance — and insurance reimbursement coverage is wildly inconsistent across plans and employers.
Calibrate's cash-pay model limits the addressable market to higher-income individuals who can absorb the cost. The pivot away from insurance left significant growth potential on the table.
MONEY TRAIL
Seed
2020 · Led by Human Ventures
$4M raised
Series A
2020 · Led by 8VC
$11M raised
Series B
2021 · Led by Tiger Global
$100M raised
Series B Extension
2022 · Led by Existing Investors
$8M raised
WHO BACKED THEM
Tiger Global led the $100M Series B in 2021. Previous backers include Human Ventures, 8VC, and BoxGroup.
The Series B was raised at a high valuation during the peak of digital health investor enthusiasm.
Related Profiles
Companies
Kaia Health
Both are digital health companies attacking the same root problem from different angles — chronic conditions that the traditional healthcare system handles poorly. Kaia targets musculoskeletal pain with AI-guided exercise, Calibrate targets obesity with GLP-1 medications and coaching. The B2B employer distribution model is central to both.
Spring Health
Spring Health and Calibrate both went the employer benefits route as their primary distribution channel, both raised large venture rounds in 2021, and both faced pressure to prove clinical outcomes justify the cost. Spring has scaled better, but the structural similarities are striking.
Head-to-Head
Compare Calibrate vs another company.